![](https://eu-images.contentstack.com/v3/assets/blt0a48a1f3edca9eb0/blt78e76f8aeb751eaa/66a7a44855af50e41cd0ac2a/Depositphotos_669290570_XL.jpg?disable=upscale&width=1200&height=630&fit=crop)
Kadimastem taps Pluri to produce therapeutic cells for ALS and diabetes
As per the agreement, contract development and manufacturing organization (CDMO) Pluri will manufacture Kadimastem’s cell therapy AstroRx for an upcoming Phase IIa clinical trial in ALS and produce cell product IsletRx for the treatment of diabetes. “ …